ZEPP — Zepp Health Corporation

Summary of Zepp Health Corporation Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $85.2 million, up 43% year-over-year, meeting the upper end of guidance.
• Full Year Revenue: $259 million, representing a 41.8% increase from $183 million in 2024.
• Gross Margin: Achieved a record of 40.4% in Q4, up from 36.8% in Q4 2024, driven by a favorable product mix and maintained pricing integrity.
• Adjusted Net Loss: $6.4 million in Q4, significantly improved from a loss of $22.5 million in Q4 2024. Full year adjusted net loss was $31.5 million, down from $56.7 million in 2024.
• Cash Position: Cash and cash equivalents increased to $113 million, up from $103 million in Q3 2025.

2. Strategic Updates and Business Highlights:

• Zepp is transitioning from a traditional hardware company to a hybrid training platform, focusing on integrating hardware, software, and data capabilities.
• Product Launches: Introduced the Amazfit Active MAX and Active 3 Premium targeting entry-level users, and the T-Rex Ultra 2 as a premium offering.
• Ecosystem Development: Enhanced Zepp OS with features like BioCharge and AI-driven training guidance to improve user engagement and retention.
• Brand Partnerships: Collaborated with elite athletes and events like HYROX to elevate brand visibility and credibility in the performance sports community.

3. Forward Guidance and Outlook:

• For Q1 2026, Zepp expects revenue between $50 million and $55 million, reflecting year-over-year growth of 30% to 43%.
• The company anticipates continued margin expansion as the premium product mix grows and operational efficiencies improve.

4. Bad News, Challenges, or Points of Concern:

• Operating expenses increased by $8 million year-over-year, attributed to fixed channel costs, provisions for bad debt, and upfront marketing investments.
• The company faces challenges from memory chip cost inflation and macroeconomic uncertainties, although it believes its pricing strategy can offset these pressures.
• There is a risk of supply chain issues affecting product availability, particularly for the Helio Strap, which did not meet demand in Q4 2025.

5. Notable Q&A Insights:

• The company plans to launch a similar number of new products in 2026 as in 2025, potentially slightly more.
• Zepp is not significantly impacted by U.S. dollar fluctuations due to diversified production locations.
• There is potential for further reductions in selling and marketing expenses as front-loaded costs normalize over time.
• The Adventure series is increasingly important for improving overall product mix and average selling price, with new models planned for 2026.

Overall, Zepp Health Corporation demonstrated strong financial performance in Q4 2025, with significant revenue growth and improved margins, while also outlining strategic initiatives and maintaining an optimistic outlook for the upcoming quarter. However, challenges related to operating expenses and supply chain management remain points of concern.